These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 20842536

  • 1. Raising suspicions with the Food and Drug Administration: detecting misconduct.
    Hamrell MR.
    Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
    [Abstract] [Full Text] [Related]

  • 2. Clinical study reflections: another view: Commentary on: "Raising suspicions with the Food and Drug Administration: detecting misconduct".
    Spitzig P.
    Sci Eng Ethics; 2010 Dec; 16(4):705-11. PubMed ID: 21052860
    [Abstract] [Full Text] [Related]

  • 3. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA, Epnere K, Bhansali N.
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [Abstract] [Full Text] [Related]

  • 4. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF, Charrow RP.
    JAMA; 1989 May 05; 261(17):2505-11. PubMed ID: 2704109
    [Abstract] [Full Text] [Related]

  • 5. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
    Seife C.
    JAMA Intern Med; 2015 Apr 05; 175(4):567-77. PubMed ID: 25664866
    [Abstract] [Full Text] [Related]

  • 6. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW, Mihaescu CM, Ayalew K, Kronstein PD, Yu B, Ning YM, Rodriguez M, Williams L, Khin NA.
    Ther Innov Regul Sci; 2022 Sep 05; 56(5):753-764. PubMed ID: 35610469
    [Abstract] [Full Text] [Related]

  • 7. What should be done about bias and misconduct in clinical trials?
    Fairman KA, Curtiss FR.
    J Manag Care Pharm; 2009 Mar 05; 15(2):154-60. PubMed ID: 19236130
    [No Abstract] [Full Text] [Related]

  • 8. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018.
    Rogers CA, Ahearn JD, Bartlett MG.
    Ther Innov Regul Sci; 2020 Sep 05; 54(5):1123-1133. PubMed ID: 32096103
    [Abstract] [Full Text] [Related]

  • 9. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS, Manukyan Z, Purohit-Sheth T, Gensler G, Okwesili P, Meeker-O'Connell A, Ball L, Marler JR.
    Clin Trials; 2014 Apr 05; 11(2):205-17. PubMed ID: 24296321
    [Abstract] [Full Text] [Related]

  • 10. US Food and Drug Administration Clinical Investigator Inspections.
    Buchmeier AD.
    Semin Oncol Nurs; 2020 Apr 05; 36(2):151000. PubMed ID: 32253049
    [Abstract] [Full Text] [Related]

  • 11. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
    Garmendia CA, Bhansali N, Madhivanan P.
    Ther Innov Regul Sci; 2018 Sep 05; 52(5):592-605. PubMed ID: 29714564
    [Abstract] [Full Text] [Related]

  • 12. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology.
    J Clin Oncol; 2003 Jun 15; 21(12):2377-86. PubMed ID: 12721281
    [Abstract] [Full Text] [Related]

  • 13. Introduction to special issue of Accountability in Research on the review and approval of biomedical research proposals: a call for a centralized national human research protections system.
    Mann H, Shamoo AE.
    Account Res; 2006 Jun 15; 13(1):1-9. PubMed ID: 16770856
    [No Abstract] [Full Text] [Related]

  • 14. Research involving children: regulations, review boards and reform.
    Gandhi R.
    J Health Care Law Policy; 2005 Jun 15; 8(2):264-330. PubMed ID: 16471026
    [No Abstract] [Full Text] [Related]

  • 15. A look at the bioresearch monitoring program: the agency perspective.
    Brisson EL.
    Food Drug Cosmet Law J; 1983 Apr 15; 38(2):184-9. PubMed ID: 11649578
    [No Abstract] [Full Text] [Related]

  • 16. Research ethics and scientific misconduct in biomedical research.
    Kansu E, Ruacan S.
    Acta Neurochir Suppl; 2002 Apr 15; 83():11-5. PubMed ID: 12442615
    [Abstract] [Full Text] [Related]

  • 17. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Apr 28; 73(82):22800-16. PubMed ID: 18567164
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Scientific misconduct in investigational drug trials.
    Shapiro MF, Charrow RP.
    N Engl J Med; 1985 Mar 14; 312(11):731-6. PubMed ID: 3974649
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.